The estimated Net Worth of William L. Macias is at least 12.7 百万$ dollars as of 21 August 2024. Dr Macias owns over 3,027 units of Immunovant Inc stock worth over 10,700,045$ and over the last 3 years he sold IMVT stock worth over 2,007,263$.
Dr has made over 17 trades of the Immunovant Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 3,027 units of IMVT stock worth 96,440$ on 21 August 2024.
The largest trade he's ever made was selling 44,568 units of Immunovant Inc stock on 11 January 2023 worth over 746,514$. On average, Dr trades about 4,838 units every 42 days since 2021. As of 21 August 2024 he still owns at least 368,332 units of Immunovant Inc stock.
You can see the complete history of Dr Macias stock trades at the bottom of the page.
Dr. William L. Macias M.D., Ph.D. is the Chief Medical Officer at Immunovant Inc.
Dr D is 63, he's been the Chief Medical Officer of Immunovant Inc since . There are 1 older and 13 younger executives at Immunovant Inc. The oldest executive at Immunovant Inc is Atul Pande, 65, who is the Independent Director.
William's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over 21,959,710$ worth of Immunovant Inc stock and bought 3,433,213 units worth 88,718,319$ . The most active insiders traders include Sciences Ltd. Roivant、Peter Salzmann、Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of 1,150,148$. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth 104,979$.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: